共 50 条
Bradykinin antagonists: new opportunities
被引:50
|作者:
Bock, MG
[1
]
Longmore, J
机构:
[1] Merck Res Labs, W Point, PA 19486 USA
[2] Merck Sharp & Dohme Ltd, Res Labs, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England
关键词:
D O I:
10.1016/S1367-5931(00)00107-1
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
The pro-inflammatory, pain producing, and cardiovascular effects of bradykinin B-2 receptor activation are well characterized. Bradykinin B-1 receptors also produce inflammation and pain. Therefore, antagonists are expected to be anti-inflammatory/analgesic drugs. Other exploitable clinical opportunities may exist. The newly discovered non-peptide B-2 receptor antagonists and the equivalent B-1 receptor pharmacological agents, which are in the pipeline, are suitable preclinical tools to properly evaluate potential utilities.
引用
收藏
页码:401 / 406
页数:6
相关论文